Document Code: SCF-API-HDAVS-BP-0001
Program Class: Host-Directed Antiviral / Immune-Resilience API Stack
Regulatory Status: Preclinical discovery blueprint; not for clinical use without IND-enabling validation.
1. Development Objective
Engineer a host-directed antiviral stack that suppresses viral permissiveness by strengthening host antiviral immunity, metabolic resilience, redox balance, mucosal defense, and post-viral tissue recovery rather than relying only on direct viral enzyme inhibition. This follows SCF stack logic: target modulation, safety harmonization, metabolic regulation, absorption enhancement, and supportive multi-node reinforcement.
2. SCF Therapeutic Hypothesis
A multi-component host-directed antiviral API stack can reduce viral replication-supportive host states by coordinating:
Axis | Host-Directed Target | Desired Effect |
Innate immunity | IFN-stimulated gene tone, TLR balance, NK-cell readiness | Faster antiviral recognition |
Inflammation | NF-κB, IL-6, TNF-α, inflammasome drift | Prevent cytokine excess |
Metabolism | AMPK, ATP/AMP balance, mitochondrial flux | Reduce viral metabolic permissiveness |
Redox | ROS buffering, NRF2-linked antioxidant response | Protect tissue and immune function |
Mucosal barrier | epithelial tight junctions, secretory IgA support | Reduce entry/propagation niche |
Recovery | ECM repair, lymphatic clearance, neuroimmune stabilization | Improve post-viral resilience |
3. Proposed Stack Architecture
SCF Role | Candidate API Class | Representative Lead | Engineering Purpose |
Target Modulator | Diterpene lactone / antiviral immunomodulator | Andrographolide analog | Host immune-pathway modulation; NF-κB/JAK-STAT balancing |
Metabolic Regulator | Nucleoside analog-like natural scaffold | Cordycepin analog | ATP/RNA-axis metabolic pressure; antiviral resilience support |
Safety Harmonizer | Triterpenoid/saponin repair scaffold | Asiaticoside derivative | Barrier repair, tissue protection, inflammatory softening |
Bioavailability Enhancer | Alkaloid absorption enhancer | Piperine microdose analog | Permeability and PK enhancement |
Redox Stabilizer | Polyphenol scaffold | Curcumin/galangin co-scaffold | ROS/NF-κB modulation; metabolic-inflammatory buffering |
Mucosal Support Agent | Beta-glucan / polysaccharide fraction | β-glucan standardized fraction | Innate immune priming and mucosal resilience |
Vietnam/Mekong candidates already identified in the SCF database include Andrographis paniculata, Curcuma longa, Centella asiatica, Piper nigrum, Panax vietnamensis, and Illicium verum, with roles including target modulation, metabolic regulation, safety harmonization, and antiviral precursor logic.
4. API Scaffold Design
Scaffold Layer | Engineering Strategy | Output |
Core antiviral-host scaffold | Semi-synthetic andrographolide or cordycepin analog | Primary host-directed antiviral candidate |
Metabolic stabilizer scaffold | Curcuminoid/galangin hybrid or nanoencapsulated polyphenol | Redox-metabolic stabilizer |
Repair scaffold | Asiaticoside-derived triterpenoid conjugate | Safety/tissue recovery module |
PK enhancer | Piperine derivative or controlled low-dose enhancer | Improved oral absorption |
Delivery scaffold | Lipid nanoparticle, mucosal tablet, or delayed-release capsule | Site-specific release |
The extraction and profiling pipeline should use solvent selection by compound polarity, HPLC/preparative purification, molecular docking, binding assays, reporter assays, Caco-2 permeability, microsome stability, and tissue-selectivity studies.
5. Pharmacological Mechanics
Category | Blueprint |
MoA | Antiviral immune resilience, anti-inflammatory control, mitochondrial stabilization, mucosal-barrier support |
MeA | NF-κB moderation, IFN-response tuning, AMPK support, ROS reduction, cytokine variance control, epithelial protection |
Primary Indications for Research | Respiratory viral infections, post-viral inflammatory syndromes, immune-resilience prophylaxis research |
Contraindication Flags | Immunosuppression, autoimmune instability, anticoagulant interaction risk, pregnancy, hepatic impairment, CYP/P-gp interaction risk |
6. SCF Synergy Metrics
Metric | Target Score | Rationale |
TSSM | 84 | Multi-node antiviral pressure without single-target resistance drift |
HSV-F² | 80 | Metabolic efficiency via mitochondrial/redox buffering |
SV-EQ | 82 | Host-pathway specificity without diffuse immune overstimulation |
MGIS | 78 | Requires optimization of oral PK and release geometry |
SPCI | 86 | Safety harmonizer and low-toxicity support agents improve tolerability |
CSI | 82 | Optimal synergistic set threshold >80 |
SCF synergy evaluation uses TSSM, HSV-F², SV-EQ, MGIS, and SPCI, mapped respectively to resistance prevention, metabolic efficiency, targeted action, pharmacokinetic optimization, and safety profile. The Combination Synergy Index is calculated as the average of these five metrics.
7. Delivery Engineering
Delivery Requirement | SCF Engineering Solution |
Oral stability | Enteric-coated capsule or bilayer tablet |
Mucosal targeting | Mucoadhesive polymer layer |
Poor solubility | Lipid nanoparticle or cyclodextrin inclusion |
Chronobiologic release | Morning immune-activation phase; evening repair phase |
Safety control | Low-dose PK enhancer; cytokine monitoring gate |
SCF development documents require delivery engineering through geometry-based carriers, chrono-catabolic timing, DBI-responsive delivery nodes, and PCR-mode release logic.
8. Biomarker Verification Panel
Domain | Biomarkers |
Viral response | viral load assay, qPCR pathogen panel, IFN-stimulated gene signature |
Immune balance | IL-6, TNF-α, IL-1β, IFN-β, NK-cell activity |
Metabolic resilience | ATP/AMP ratio, lactate, AMPK activation, mitochondrial membrane potential |
Redox | ROS, GSH/GSSG, NRF2-response markers |
Safety | CBC, CMP, ALT/AST, bilirubin, creatinine, coagulation panel |
Post-viral recovery | CRP, ferritin, D-dimer, HRV, fatigue/function scales |
9. Preclinical Development Plan
Stage | Required Studies |
Discovery | SMILES generation, docking, MoA/MeA profiling |
In vitro | antiviral host-cell assays, cytokine panels, Caco-2, hepatocyte toxicity |
Ex vivo | PBMC immune-response profiling, mucosal epithelial models |
In vivo | PK/PD, dose-range finding, toxicology, viral challenge model where appropriate |
IND-enabling | GLP tox, safety pharmacology, CMC, stability, interaction studies |
SCF laboratory validation should include potency curves, flow cytometry, cytokine profiling, qPCR, Seahorse metabolic flux, ROS kinetics, live-cell imaging, structural mapping, and PK curve fitting.
10. FDA Translation Path
Regulatory Module | Blueprint Output |
Pre-IND package | Mechanism dossier, CMC plan, toxicology rationale |
IND | Preclinical pharmacology, GLP toxicology, manufacturing controls, clinical protocol |
Phase I | Safety, PK/PD, immune-biomarker response |
Phase II | Dose-ranging, antiviral/host-response endpoints |
Phase III | Confirmatory safety and efficacy |
NDA / 505(b)(1) or 505(b)(2) | Depends on novelty of scaffold and reliance on existing data |
11. Development Decision Gates
Gate | Pass Criteria |
G1 Mechanistic Fit | Clear host-directed antiviral pathway map |
G2 Synergy | CSI ≥80 with no antagonistic interaction |
G3 Safety | No cytokine overshoot; acceptable hepatic/CYP profile |
G4 PK | Oral bioavailability and exposure within target range |
G5 Translational Readiness | Biomarker-linked endpoint strategy and scalable CMC |
MASTER INDEX
SCF-API-HDAVS-BP-0001 — Host-Directed Antiviral Stack API Engineering Blueprint
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-ETHBIO-WF-0001 — Ethnobioprospecting + Synergistic API Design Workflow
SCF-API-DP-0001 — API Discovery Profile Template
SCF-CRD-WORKFLOW-0001 — Clinical Research & Development Workflow
SCF-HDAVS-CMC-0001 — Proposed CMC Development Module
SCF-HDAVS-IND-0001 — Proposed IND Translation Module